Latest news

Nukleærmedisin med presisjonsdiagnostikk og persontilpasset behandling. Nukleærmedisin omfatter både diagnostikk og behandling ved bruk...

CONNECT’s newest partner, GSK, sponsors the Cancer Crosslinks 2022, and is increasing its focus on oncology and hematology. These are...

Clinical Decision Support Systems: useful for what and for whom? In his introduction, Eivind Hovig, Professor at the Centre for...

CONNECTs partner Eli Lilly & Company is now offering participants of the IMPRESS study a new and promising medicine.

CONNECT seminar: The new EU regulations on IVDR – how to be prepared?

This year’s King Olav V’s Prize for Cancer Research will go to Professor Bjørn Tore Gjertsen, one of CONNECT’s Steering Committee...

Norge står i en internasjonal særstilling for å kunne samarbeide godt i helsesektoren, men det krever at politikerne tør å satse, skriver...

Connect had the pleasure of participating at Arendalsuka. Here you can find the debates and conversations we had during the event....

One of the largest pharmaceutical companies enters the precision cancer study IMPRESS in Norway.